Anaphylaxis : A 2023 practice parameter update
Copyright © 2023. Published by Elsevier Inc..
This practice parameter update focuses on 7 areas in which there are new evidence and new recommendations. Diagnostic criteria for anaphylaxis have been revised, and patterns of anaphylaxis are defined. Measurement of serum tryptase is important for diagnosis of anaphylaxis and to identify underlying mast cell disorders. In infants and toddlers, age-specific symptoms may differ from older children and adults, patient age is not correlated with reaction severity, and anaphylaxis is unlikely to be the initial reaction to an allergen on first exposure. Different community settings for anaphylaxis require specific measures for prevention and treatment of anaphylaxis. Optimal prescribing and use of epinephrine autoinjector devices require specific counseling and training of patients and caregivers, including when and how to administer the epinephrine autoinjector and whether and when to call 911. If epinephrine is used promptly, immediate activation of emergency medical services may not be required if the patient experiences a prompt, complete, and durable response. For most medical indications, the risk of stopping or changing beta-blocker or angiotensin-converting enzyme inhibitor medication may exceed the risk of more severe anaphylaxis if the medication is continued, especially in patients with insect sting anaphylaxis. Evaluation for mastocytosis, including a bone marrow biopsy, should be considered for adult patients with severe insect sting anaphylaxis or recurrent idiopathic anaphylaxis. After perioperative anaphylaxis, repeat anesthesia may proceed in the context of shared decision-making and based on the history and results of diagnostic evaluation with skin tests or in vitro tests when available, and supervised challenge when necessary.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology - 132(2024), 2 vom: 18. Feb., Seite 124-176 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 05.02.2024 Date Revised 05.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.anai.2023.09.015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365993816 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365993816 | ||
| 003 | DE-627 | ||
| 005 | 20240205231957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.anai.2023.09.015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1281.xml |
| 035 | |a (DE-627)NLM365993816 | ||
| 035 | |a (NLM)38108678 | ||
| 035 | |a (PII)S1081-1206(23)01304-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Golden, David B K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anaphylaxis |b A 2023 practice parameter update |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2024 | ||
| 500 | |a Date Revised 05.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a This practice parameter update focuses on 7 areas in which there are new evidence and new recommendations. Diagnostic criteria for anaphylaxis have been revised, and patterns of anaphylaxis are defined. Measurement of serum tryptase is important for diagnosis of anaphylaxis and to identify underlying mast cell disorders. In infants and toddlers, age-specific symptoms may differ from older children and adults, patient age is not correlated with reaction severity, and anaphylaxis is unlikely to be the initial reaction to an allergen on first exposure. Different community settings for anaphylaxis require specific measures for prevention and treatment of anaphylaxis. Optimal prescribing and use of epinephrine autoinjector devices require specific counseling and training of patients and caregivers, including when and how to administer the epinephrine autoinjector and whether and when to call 911. If epinephrine is used promptly, immediate activation of emergency medical services may not be required if the patient experiences a prompt, complete, and durable response. For most medical indications, the risk of stopping or changing beta-blocker or angiotensin-converting enzyme inhibitor medication may exceed the risk of more severe anaphylaxis if the medication is continued, especially in patients with insect sting anaphylaxis. Evaluation for mastocytosis, including a bone marrow biopsy, should be considered for adult patients with severe insect sting anaphylaxis or recurrent idiopathic anaphylaxis. After perioperative anaphylaxis, repeat anesthesia may proceed in the context of shared decision-making and based on the history and results of diagnostic evaluation with skin tests or in vitro tests when available, and supervised challenge when necessary | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 7 | |a Epinephrine |2 NLM | |
| 650 | 7 | |a YKH834O4BH |2 NLM | |
| 650 | 7 | |a Allergens |2 NLM | |
| 700 | 1 | |a Wang, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Waserman, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Akin, Cem |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Ronna L |e verfasserin |4 aut | |
| 700 | 1 | |a Ellis, Anne K |e verfasserin |4 aut | |
| 700 | 1 | |a Greenhawt, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Lang, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Ledford, Dennis K |e verfasserin |4 aut | |
| 700 | 1 | |a Lieberman, Jay |e verfasserin |4 aut | |
| 700 | 1 | |a Oppenheimer, John |e verfasserin |4 aut | |
| 700 | 1 | |a Shaker, Marcus S |e verfasserin |4 aut | |
| 700 | 1 | |a Wallace, Dana V |e verfasserin |4 aut | |
| 700 | 1 | |a Abrams, Elissa M |e verfasserin |4 aut | |
| 700 | 1 | |a Bernstein, Jonathan A |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Derek K |e verfasserin |4 aut | |
| 700 | 1 | |a Horner, Caroline C |e verfasserin |4 aut | |
| 700 | 1 | |a Rank, Matthew A |e verfasserin |4 aut | |
| 700 | 1 | |a Stukus, David R |e verfasserin |4 aut | |
| 700 | 0 | |a Collaborators |e verfasserin |4 aut | |
| 700 | 1 | |a Burrows, Alyssa G |e verfasserin |4 aut | |
| 700 | 1 | |a Cruickshank, Heather |e verfasserin |4 aut | |
| 700 | 0 | |a Workgroup Contributors |e verfasserin |4 aut | |
| 700 | 1 | |a Golden, David B K |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Akin, Cem |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Ronna L |e verfasserin |4 aut | |
| 700 | 1 | |a Ellis, Anne K |e verfasserin |4 aut | |
| 700 | 1 | |a Greenhawt, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Lang, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Ledford, Dennis K |e verfasserin |4 aut | |
| 700 | 1 | |a Lieberman, Jay |e verfasserin |4 aut | |
| 700 | 1 | |a Oppenheimer, John |e verfasserin |4 aut | |
| 700 | 1 | |a Shaker, Marcus S |e verfasserin |4 aut | |
| 700 | 1 | |a Wallace, Dana V |e verfasserin |4 aut | |
| 700 | 1 | |a Waserman, Susan |e verfasserin |4 aut | |
| 700 | 0 | |a Joint Task Force on Practice Parameters Reviewers |e verfasserin |4 aut | |
| 700 | 1 | |a Abrams, Elissa M |e verfasserin |4 aut | |
| 700 | 1 | |a Bernstein, Jonathan A |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Derek K |e verfasserin |4 aut | |
| 700 | 1 | |a Ellis, Anne K |e verfasserin |4 aut | |
| 700 | 1 | |a Golden, David B K |e verfasserin |4 aut | |
| 700 | 1 | |a Greenhawt, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Horner, Caroline C |e verfasserin |4 aut | |
| 700 | 1 | |a Ledford, Dennis K |e verfasserin |4 aut | |
| 700 | 1 | |a Lieberman, Jay |e verfasserin |4 aut | |
| 700 | 1 | |a Rank, Matthew A |e verfasserin |4 aut | |
| 700 | 1 | |a Shaker, Marcus S |e verfasserin |4 aut | |
| 700 | 1 | |a Stukus, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Julie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology |d 1995 |g 132(2024), 2 vom: 18. Feb., Seite 124-176 |w (DE-627)NLM075127695 |x 1534-4436 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2024 |g number:2 |g day:18 |g month:02 |g pages:124-176 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.anai.2023.09.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2024 |e 2 |b 18 |c 02 |h 124-176 | ||